TG Therapeutics Lifts Full-Year 2026 Global Revenue Outlook to $1 Billion as BRIUMVI Sales Jump 52%

TG Therapeutics raised its full-year 2026 global revenue guidance to $1 billion on its third-quarter earnings call, held on November 9, 2026, after U.S. BRIUMVI revenue rose 52% year over year to $233 million. The Motley Fool covered the call. TG Therapeutics is a commercial-stage biopharmaceutical company that develops and markets BRIUMVI (ublituximab-xiiy), a glycoengineered anti-CD20 monoclonal antibody approved by the FDA for relapsing multiple sclerosis, according to akta.pro company records.

Inside TG Therapeutics' Raised 2026 Outlook

Chief Financial Officer Sean Power said the company raised its full-year outlook to $915 million to $920 million in U.S. BRIUMVI net product revenue and approximately $1 billion in total global revenue, including projected payments from its ex-U.S. partner. "Looking ahead, we're raising our full-year revenue outlook to $915 million to $920 million in U.S. BRIUMVI net product revenue and approximately $1 billion in total global revenue, including projected payments from our ex-U.S. partner," Power said.

Chief Commercial Officer Adam Waldman said self-administered treatments account for roughly 35% of new anti-CD20 therapy starts, and that a quarterly subcutaneous option would let TG Therapeutics reach patients who prefer home administration without replacing its existing intravenous business. "We believe the addition of subcu can more than double BRIUMVI peak sales opportunity by opening an entirely new segment of the anti-CD20 market where we don't currently participate," Waldman said.

Waldman also said management plans to combine two separate starting infusions into a single session, a change it expects to create demand tailwinds in the second half of 2027. "Based on physician feedback and our market research, we believe eliminating the second initiation infusion could become a meaningful driver of additional demand, providing further potential tailwinds to our IV business in the second half of '27 and beyond," he said.

TG Therapeutics' Cash and Patent Position

TG Therapeutics reported $557 million in cash and investments, and Chairman and Chief Executive Officer Michael Weiss said patent protection extends into the mid-2040s. "Our objective remains clear: to build a company capable of repeatedly creating value through scientific innovation, disciplined execution and thoughtful investments that generate attractive long-term returns," Weiss said.

Company records show TG Therapeutics completed enrollment in April 2026 in the Phase 3 trial of subcutaneous ublituximab for relapsing MS, positioning a self-administered formulation with a potential 2027 launch. In March 2026 the company secured a $750 million five-year senior secured credit facility from Blue Owl Capital, delivering $500 million in non-dilutive capital after retiring prior debt and expandable to $1 billion, the same records show.

Earlier TG Therapeutics Revenue Milestones

In September 2026, AInvest reported that BRIUMVI was approaching $1 billion in annual U.S. sales while net income fell to $7.8 million in the second quarter of 2026, a margin below 6%. Earlier that month, AInvest reported that TG Therapeutics' stock fell 16% after second-quarter earnings per share missed, despite $228 million in BRIUMVI revenue growth and raised 2026 guidance of $890 million to $905 million.

What Comes Next for BRIUMVI

TG Therapeutics expects the single-dose IV initiation change to create demand tailwinds in the second half of 2027, and company records describe a potential 2027 launch for the subcutaneous formulation.